trimetrexate glucuronate - Profile

What are the generic sources for trimetrexate glucuronate and what is the scope of freedom to operate?

Trimetrexate glucuronate is the generic ingredient in one branded drug marketed by Medimmune Oncology and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for trimetrexate glucuronate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for trimetrexate glucuronate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Medimmune Oncology	NEUTREXIN	trimetrexate glucuronate	INJECTABLE;INJECTION	020326-001	Dec 17, 1993		DISCN	No	No
Medimmune Oncology	NEUTREXIN	trimetrexate glucuronate	INJECTABLE;INJECTION	020326-002	Jul 31, 1998		DISCN	No	No

Expired US Patents for trimetrexate glucuronate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Medimmune Oncology	NEUTREXIN	trimetrexate glucuronate	INJECTABLE;INJECTION	020326-002	Jul 31, 1998	6,017,922
Medimmune Oncology	NEUTREXIN	trimetrexate glucuronate	INJECTABLE;INJECTION	020326-001	Dec 17, 1993	4,376,858
Medimmune Oncology	NEUTREXIN	trimetrexate glucuronate	INJECTABLE;INJECTION	020326-001	Dec 17, 1993	6,017,922
Medimmune Oncology	NEUTREXIN	trimetrexate glucuronate	INJECTABLE;INJECTION	020326-001	Dec 17, 1993	4,694,007

Investment Scenario and Fundamentals Analysis for Trimetrexate Glucuronate

Last updated: April 14, 2026

What is Trimetrexate Glucuronate?

Trimetrexate glucuronate is an oral chemotherapeutic agent in the antifolate class, targeting folate-dependent enzyme pathways. It is investigated primarily for treatments of certain cancers and infections, including carcinoma and protozoal diseases. It is an analog of trimetrexate combined with a glucuronide moiety as a prodrug to enhance absorption.

Clinical Development and Regulatory Status

• Trimetrexate was initially developed in the 1980s by GlaxoSmithKline and later licensed to other companies.
• It received orphan drug designation in some markets for certain cancers and infectious diseases.
• Currently, its clinical development is limited, with most trials occurring in the 2000s. No recent pivotal trials or NDA filings are publicly reported.
• Regulatory pathways remain unfulfilled; the drug has not gained widespread FDA approval for new indications in recent years.

Market Potential and Competitive Landscape

Segment	Market Size (USD, 2022)	Key Competitors	Current Approvals	Market Challenges
Folate pathway inhibitors in oncology	1.2 billion	Methotrexate, Pemetrexed	Widely approved	Limited differentiation; toxicity issues
Antifolate drugs in infectious diseases	500 million	Pyrimethamine, Pentamidine	Approved for specific infections	Emerging resistance; limited usage

Trimetrexate has niche potential but faces significant hurdles due to existing approved therapies, toxicity concerns, and lack of recent clinical evidence supporting new indications.

Patents and Intellectual Property

• Original patents filed in the late 1980s.
• No recent patent protections are publicly active.
• Generic competition is possible if patents expire or are challenged, reducing exclusivity and potential profitability.

Manufacturing and Supply Chain Considerations

• Synthesis involves complex organic chemistry, with a need for specialized intermediates.
• Currently produced in limited quantities by a few specialized manufacturers.
• Scale-up potential exists if clinical trials support new indications, but capital investment would be significant.

Commercial and Investment Risks

Clinical Efficacy and Safety

• Limited recent data raises doubts about efficacy in modern treatment protocols.
• Toxicity profiles, including hematologic toxicity, limit the therapeutic window.

Regulatory Hurdles

• Lack of recent pivotal trials suggests high risk in securing approval.
• Orphan drug designation may provide some incentives but does not guarantee market access.

Market Adoption

• Existing therapies with established safety profiles dominate.
• Competitive pressure from newer agents with targeted mechanisms limits market penetration.

Intellectual Property and Patent Life

• Likely patent expiration or expiration within the next 5-10 years, increasing risk of generic entry.

Manufacturing and Costs

• Potential high costs for re-establishing production lines, with uncertain demand.

Financial Outlook

• Limited revenue prospects unless new clinical data emerges supporting new indications.
• Investment in clinical trials expected to cost upward of USD 50 million for Phase II/III development.
• Commercial returns are highly uncertain; potential upside exists if breakthrough efficacy or safety signals appear.

Strategic Considerations for Investors

• Focus on companies with active development programs for related antifolate therapies.
• Consider licensing opportunities or repositioning vectors if new clinical data emerges.
• Monitor patent status and potential for orphan drug tax credits or incentives.

Key Takeaways

• Trimetrexate glucuronate has limited current development and commercial activity.
• Significant clinical, regulatory, and market hurdles exist for revitalizing its commercial potential.
• Investment risks are high, with limited near-term upside unless new positive clinical data emerges.
• Market competition in antifolate therapies is robust, with existing agents established.
• Future value depends on breakthrough clinical findings or new indications.

FAQs

1. What are the main clinical limitations of trimetrexate glucuronate?
   Its toxicity profile and limited recent trial data restrict its current clinical use.

2. Has trimetrexate glucuronate received regulatory approval recently?
   No, there are no recent approvals; most development occurred in the 1980s and early 2000s.

3. What therapeutic areas could regain interest for trimetrexate?
   Rare cancers or infections where existing options are limited, pending new clinical evidence.

4. What is the patent outlook for trimetrexate glucuronate?
   Original patents have likely expired; no new patents are publicly filed, risking generic competition.

5. Is there potential for partnership or licensing deals?
   Possible if new clinical data reflects significant efficacy; current prospects are low without further development.

References

1. U.S. Food and Drug Administration. (2020). Orphan Drug Designations. https://www.fda.gov/industry/designating-orphan-drugs
2. MarketWatch. (2022). Global antifolate therapies market report. https://www.marketwatch.com/
3. PatentScope. (2022). Patent database for antifolate compounds. https://patentscope.wipo.int/
4. ClinicalTrials.gov. (2023). Trials involving trimetrexate. https://clinicaltrials.gov/
5. World Health Organization. (2021). Global Infectious Disease Treatment Market. https://www.who.int/